跟进：世卫组织称刚果（金）埃博拉确诊升至10668例：将两种本迪布焦病毒候选疫苗纳入临床试验

金沙萨 — 世界卫生组织11月6日发布的疫情通报显示，刚果民主共和国本轮埃博拉疫情截至11月3日累计确诊10,668例、死亡5,198人，粗病死率48.7%，康复2,881人。疫情已扩散至8个省的67个卫生区，东北部的伊图里省仍是中心。这是刚果（金）有记录以来最大的一次埃博拉疫情，也是全球第二大埃博拉疫情。

本轮疫情由本迪布焦病毒引发，这是埃博拉病毒属六个种之一，目前没有针对它的获批疫苗和特效治疗药物。

世卫组织的专家组已建议把两种专为本迪布焦病毒设计的候选疫苗加入正在刚果（金）进行的 Tumaini 临床试验：一种是牛津大学与印度血清研究所合作的 ChAdOx1，另一种是 Moderna 公司的 mRNA-1469。这是本迪布焦病毒疫苗首次在真实疫情中接受评估。两种候选疫苗仍需刚果（金）监管部门批准，初步结果预计2027年初得出。

Tumaini 试验由刚果（金）国家生物医学研究所牵头，10月23日在布尼亚启动，采用环围接种方式，向确诊患者的接触者及其接触者提供疫苗；此前被评估的第一种疫苗是针对扎伊尔种的 Ervebo。

世卫组织指出，社区内死亡比例偏高、尤其是幼儿，显示早期病例发现仍有缺口。GSM 此前报道，美国疾控中心评估截至10月31日确诊10,498例，并认为多地高强度持续传播是最可能的情景。

关联：跟进：CDC评估刚果（金）埃博拉确诊10,498例：最可能情景为多地高强度持续传播

（来源：世界卫生组织）

Follow-up: WHO Puts DR Congo Ebola Cases at 10,668, Adds Two Bundibugyo-Specific Vaccine Candidates to Trial

KINSHASA — The World Health Organization's Disease Outbreak News of November 6 put the Democratic Republic of Congo's current Ebola outbreak at 10,668 confirmed cases and 5,198 deaths as of November 3, a crude case fatality ratio of 48.7 percent, with 2,881 recoveries. The outbreak has spread to 67 health zones in eight provinces, with Ituri province in the northeast remaining the epicentre. It is the largest Ebola outbreak ever recorded in the DRC and the second-largest globally.

The outbreak is caused by Bundibugyo virus, one of six known species in the Ebola genus, for which there is no approved vaccine or specific therapy.

WHO expert groups have recommended adding two vaccine candidates designed specifically against Bundibugyo virus to the Tumaini clinical trial under way in the country: ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469. It is the first time vaccines made specifically for Bundibugyo virus will be evaluated during an active outbreak. Both candidates still require approval from Congolese regulators, with initial results expected in early 2027.

The Tumaini trial, led by the DRC's Institut National de Recherche Biomédicale, began on October 23 in Bunia and uses ring vaccination, offering vaccine to contacts of confirmed patients and their contacts. The first vaccine being evaluated in the trial is Ervebo, licensed against the Zaire species.

WHO noted that a high proportion of deaths are occurring in communities rather than treatment centres, particularly among young children, indicating gaps in early case detection. GSM previously reported the US CDC's assessment of 10,498 confirmed cases as of October 31, with sustained high-intensity spread in multiple areas as the most likely scenario.

Related: Follow-up: CDC Assesses Congo Ebola Outbreak at 10,498 Cases, Sees Sustained High-Intensity Spread as Most Likely Scenario

(Source: World Health Organization)

来源：世界卫生组织

发布：GSM·美国（发布链接）

图片来源：图：2026年刚果（金）本迪布焦病毒埃博拉疫情分布图，按卫生区统计累计病例，数据截至2026年10月19日至20日。CC0。 / Map: Cumulative cases of the 2026 Bundibugyo virus Ebola outbreak in the Democratic Republic of Congo by health zone; data as of October 19-20, 2026. CC0.

GSM Global · 本篇英文版 English edition of this story

本频道最新更多 ›

伊朗为「两天重启谈判」方案辩护：巴盖伊称要求美方先解除制裁与海上封锁并不无理2026-11-09阿联酋航空取消11月8日迪拜往返利雅得与达曼全部航班：原定当日复飞未成，迪拜飞利雅得航线停飞延至11月16日2026-11-09

← 返回世界　全部新闻　关于我们